Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical-stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. Nimbus Therapeutics designs highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer, and immune-inflammatory disorders.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 12, 2022 | Series Unknown | $125M | 10 | — | — | Detail |
Jul 13, 2021 | Series Unknown | $105M | 7 | Biotechnology Value Fund | — | Detail |
Oct 14, 2020 | Series Unknown | $60M | 2 | — | — | Detail |
Jun 5, 2018 | Series C | $65M | 7 | SR One | — | Detail |
Mar 19, 2015 | Series B | $43M | 6 | Lightstone Ventures Pfizer Venture Investments | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Access Biotechnology | — | Series Unknown |
Atlas Venture | — | Series Unknown |
Bain Capital Life Sciences | — | Series Unknown |
Bill Gates | — | Series Unknown |
Biotechnology Value Fund | — | Series Unknown |
Lightstone Ventures | — | Series Unknown |
Pfizer Venture Investments | — | Series Unknown |
RA Capital Management | — | Series Unknown |
SR One | — | Series Unknown |
SV Health Investors | — | Series Unknown |